Latest news with #OC
Graziadaily
10 hours ago
- Entertainment
- Graziadaily
Yes, You Have Seen Carrie's Hot Gardener Before
After months of anticipation, And Just Like That is finally back on our screens for a third season. The show has already got hit ratings on Rotten Tomatoes, becoming the highest-ranked season so far. Many reviews are saying season three has finally found its footing as a proper sequel to the original show. The new season sees Carrie move into an incredible Gramercy Park West townhouse, leading to a host of encounters with new men. One of these is a hot new gardener, Adam (played by Logan Marshall-Green), whose jokey demeanour becomes a fun contrast to Carrie's grumpy downstairs neighbour. But where have we seen Logan before? Logan Marshall-Green is an actor, who is best known for his role as Trey Atwood in the second and third season of the OC. Logan was born in Charleston, South Carolina, and raised in Rhode Island. He went to the National Theater Institute in Waterford, Connecticut before graduating with a Master's in Fine Arts from New York University's Graduate Acting Program at the Tisch School of the Arts. NEW YORK, NY - AUGUST 01: Logan Marshall-Green is seen on the set of the series 'And Just Like That' on August 01, 2024 in New York City. (Photo by Jose Perez/Bauer-Griffin/GC Images) ©Jose Perez/Bauer-Griffin/GC Images Logan has often been compared to fellow actor Tom Hardy. While he has acknowledged the similarities between them, he has previously pointed out he actually has a twin-brother called Taylor. He told 'I'd be honoured to be in the same sentence as Tom Hardy. I've been a twin since the day I was born - fraternal, but we look a lot alike - so I've already been mixed up with another man my entire life.' Logan Marshall-Green was born on 1 November 1976, making him 48-years-old. As well as his role in the OC, Logan has had roles in other TV shows including Traveler, Dark Blue, The Defeated and Quarry. He's also had starring roles in the films Devil, Prometheus, The Invitation, Spider-Man: Homecoming, and Upgrade. ©Jose Perez/Bauer-Griffin/GC Images Fans were excited that Logan was starring in AJLT last year, after he was pictured on set with Sarah Jessica Parker. One fan account re-shared a picture that shows Logan cuddling Carrie's cat, with the caption: 'Oh my word, my heart!!!' At the time, it was unclear what role Logan would play, and some people speculated he could be a potential love interest of Carrie's. However, now we know he is Carrie's gardener, who has a penchant for silly T-shirts and a hilarious - and slightly sassy - personality.
Yahoo
2 days ago
- Business
- Yahoo
ASCO 2025: GSK's Jemperli fails to show OS benefit in 1L advanced ovarian cancer
At the American Society of Clinical Oncology (ASCO) Annual Meeting 2025, held from 31 May to 3 June in Chicago, Illinois, updated efficacy and safety data from the international, double-blind, randomised Phase III FIRST clinical trial were presented on 1 June. The trial evaluated the combination of GSK's Jemperli (dostarlimab), a monoclonal antibody targeting programmed cell death protein 1, and Zejula (niraparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with platinum-based chemotherapy (PtCh) as a first-line therapy in patients with stage III and IV epithelial ovarian cancer (OC). OC is a deadly gynaecological malignancy, with approximately 90% of cases classified as epithelial. According to GlobalData's Ovarian Cancer: Opportunity Assessment and Forecast report, the number of diagnosed incident cases of OC in the seven major markets (7MM: France, Germany, Italy, Japan, Spain, the UK and the US) is expected to rise from 67,762 in 2025 to 71,308 by 2032. In the FIRST/ENGOT-OV44 study, a total of 1,138 patients with advanced OC were randomised (1:1:2) to experimental arm 1 (PtCh + placebo and placebo maintenance; dropped from the study due to PARP inhibitor approval), arm 2 (PtCh + placebo and Zejula maintenance; n=385), and comparator arm 3 (PtCh + Jemperli and Jemperli/Zejula maintenance; n=753). The efficacy of arms 2 and 3 (intention-to-treat population) was evaluated based on the primary endpoint - investigator-assessed progression-free survival (PFS). The PFS showed a statistically significant difference between arm 3 and arm 2 (median 20.6 months versus 19.2; hazard ratio [HR] 0.85, 95% confidence interval [CI], 0.73–0.99, P = 0.0351), with a median duration follow-up of 53.1 months. The key secondary endpoint, overall survival (OS), had reached 57% maturity and was not statistically significant (median 44.4 versus 45.4 months; HR 1.01, 95% CI, 0.86–1.19, P = 0.9060). In the maintenance period, treatment-related adverse events above Grade 3 were reported in 41.1% of patients in arm 3 and 37.2% in arm 2. The study concludes that adding Jemperli to PtCh and Zejula provides a statistically significant but clinically modest PFS benefit, with no improvement in OS for newly diagnosed advanced OC patients. The result was not unexpected, as immune checkpoint inhibitors have shown limited efficacy in OC, which is considered poorly immunogenic. At the end of 2024, Merck & Co's Keytruda (pembrolizumab) and AstraZeneca's Lynparza (olaparib) also failed to meet expectations in the KEYLYNK-001 study as a first-line therapy for OC, showing no OS benefit, similar to findings from the FIRST/ENGOT-OV44 study. Currently, no anti-PD-(L)1 therapies are approved for OC, and demonstrating a positive OS outcome is critical to gaining market share in this broad indication. A key difference between the two studies lies in patient selection. KEYLYNK-001 enrolled patients with breast cancer gene (BRCA) mutations, whereas the FIRST/ENGOT-OV44 trial included all-comers. To improve its chances of success, GSK made multiple modifications to the FIRST/ENGOT-OV44 trial design, including delaying readouts by several years. Initially, the primary endpoint was PFS in PD-L1-positive patients. In 2020, it was split into two groups, PFS in all-comers and PD-L1 expressers, before ultimately shifting the focus solely to all-comers. Another concern is the Jemperli and Zejula combination in the second-line setting for OC. A Phase III trial (NSGO-AVATAR) evaluating this combination was withdrawn due to a lack of financial support, suggesting GSK may not be optimistic about its prospects in the broader gynaecological cancer space. According to GlobalData's analyst consensus forecast, global sales for Jemperli and Zejula are projected to reach $2.56 billion and $1.26 billion, respectively, by 2030. In comparison, AstraZeneca's Lynparza and blockbuster PD-1 blocker Merck's Keytruda are expected to reach global sales of $2.4 billion and $22.71 billion, respectively. GSK acquired both Jemperli (co-developed with AnaptysBio) and Zejula through its $5.31 billion acquisition of Tesaro in 2019. After the FDA's accelerated approval in 2021 for patients with mismatch repair-deficient endometrial cancer as a second-line treatment, Jemperli has become a cornerstone of GSK's cancer portfolio alongside Zejula. In its most recent financial report, Jemperli sales increased 15% to $285 million in Q1 2025 due to broad-label expansion in first-line endometrial cancer regardless of biomarker status in the US. However, Jemperli holds a distinct advantage with its OS data over its main competitor, Keytruda, which also secured broad expansion in 2024. To expand Jemperli's success beyond endometrial cancer, GSK will need to wait for positive Phase III results from other ongoing clinical trials: GALAXIES LUNG 301, AZUR-2, MITO 33, JADE, ROCSAN and COSTAR Lung. "ASCO 2025: GSK's Jemperli fails to show OS benefit in 1L advanced ovarian cancer" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New Indian Express
7 days ago
- Politics
- New Indian Express
Karnataka cabinet to take call on OC for power linking
BENGALURU: Energy Minister KJ George on Thursday said the state cabinet will take a decision on removing the mandate requiring obtaining Occupancy Certificate (OC) to get power connection. He said the government understands the challenges faced by industries and homes due to mandate. The issue has been deliberated with the chief secretaries and a report with possible solutions has been prepared to be placed before the cabinet for approval. He was speaking during an interaction with party workers at the KPCC head office. George said the government had mandated the need for an OC following Supreme Court directions. 'However, to address the challenges, a by-law amendment is being considered. The issue was recently discussed in a cabinet meeting,' he said. On de-linking old RR numbers incase of new rentals to avail the Gruha Jyothi scheme, George said the process is now available online and incase people are facing problems, they can approach the jurisdictional officials.
Yahoo
29-05-2025
- Business
- Yahoo
Brokers Suggest Investing in Owens Corning (OC): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Let's take a look at what these Wall Street heavyweights have to say about Owens Corning (OC) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. Owens Corning currently has an average brokerage recommendation (ABR) of 1.69, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 16 brokerage firms. An ABR of 1.69 approximates between Strong Buy and Buy. Of the 16 recommendations that derive the current ABR, 10 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 62.5% and 6.3% of all recommendations. Check price target & stock forecast for Owens Corning here>>>The ABR suggests buying Owens Corning, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation. Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation. In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement. Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision. Although both Zacks Rank and ABR are displayed in a range of 1-5, they are different measures altogether. The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5. It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them. On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks. There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices. Looking at the earnings estimate revisions for Owens Corning, the Zacks Consensus Estimate for the current year has declined 6.1% over the past month to $13.24. Analysts' growing pessimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates lower, could be a legitimate reason for the stock to plunge in the near term. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Owens Corning. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, it could be wise to take the Buy-equivalent ABR for Owens Corning with a grain of salt. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Owens Corning Inc (OC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Hans India
27-05-2025
- General
- Hans India
Poor response to ‘Sarala Cauvery' scheme
Bengaluru: Bengaluru's ambitious 'Sarala Cauvery' scheme, launched to make Cauvery water connections more affordable, has seen poor public response with only 144 applications received so far. Introduced under the Cauvery Phase 5 project, the scheme allows residents to pay 20 per cent of the connection fee upfront and the rest in 12 monthly EMIs. However, many citizens are hesitant due to issues such as lack of occupancy certificates, high initial costs, and previous disputes with builders. Despite a target of 4 lakh connections, the initiative is struggling to gain traction. Under the Cauvery 5th phase scheme, 775 MLD of water has been brought and is being supplied to 110 villages and other areas. The amount of water supplied to the city has increased to 2,225 million litres from this scheme. The target was to provide 4 lakh water connections under the Cauvery 5th phase scheme. The water board is struggling to reach this target and the 'Sarala Cauvery' scheme was launched on May 9. However, this too is not getting the expected response from the people. Those who are unable to pay the full pro-rata fee have been given a two-month opportunity to get water connections under the 'Sarala Cauvery' scheme. They have been allowed to pay 20 per cent of the demand notice issued by the water board and the remaining 80 per cent of the fee has been paid through EMI for 12 months. This opportunity is not given to industrial and commercial buildings. So far, about 83,000 water connections have been sanctioned under the Cauvery Phase 5 scheme. Out of these, 59,273 connections have been given in 110 villages. However, only 144 applications have been submitted under the 'Sarala Cauvery' scheme. Out of these, 57 connections have been provided. Residents of the metropolis are not being provided with relevant documents including the Occupancy Certificate (OC) to get water connections. Some others are lamenting that they cannot afford the pro-rata fee. Thus, they are resorting to tanker water provided at a fixed rate by the water board itself. If you get a water connection, you have to pay a fee even if you don't use the water. Also, the water fee has also increased. They are hesitating to take advantage of the 'Sarala Cauvery' scheme because they have to spend money even to get the connection. Some apartment residents have already paid the water connection fee to the builders in the beginning. However, the builders have not paid that money to the Water Board. Therefore, the residents are hesitating to pay the money again. The water board has proposed to provide Cauvery connection to small houses and plot owners by paying a fee of Rs 1000. It is intended to provide connection to small houses with an area of 600 sq feet and less. Water board sources said that 6000-8000 such houses have been identified. The fee for residential buildings including apartments is at Rs 400 (per sq ft), non-residential, commercial buildings - Rs 600 (per sq ft) Many people have been delayed in submitting their applications due to inability to provide possession certificate and other documents. There is still time to apply under the Saral Cauvery scheme. It has been decided to provide water connection to 6000-8000 small houses for Rs 1000, said Dr Ram Prasath Manohar, Chairman of the Water Board
